8:31 AM ET
8-K
Clinical Trial Data
Vir Biotechnology Clinical Trial Data
Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.